Condition: Radiation Necrosis · High Grade Glioma (III or IV) · Brain Metastasases · Sponsor: The Netherlands Cancer Institute
Cerebral radiation necrosis (CRN) is a severe complication of high-dose radiation for brain metastases (BM) or glioma, which can potentially cause significant neurologic symptoms leading to serious morbidity and impaired quality of life (QoL). The first-line therapy for symptomatic CRN (sCRN) is corticosteroids, primarily dexamethasone, which often leads to complications, refractory symptoms, and interference with anti-cancer treatment. Since 2017, bevacizumab, an antibody against Vascular Endothelial Growth Factor (VEGF), has been used in a second-line treatment setting for refractory sCRN. A small randomized clinical trial (RCT) has shown that bevacizumab significantly diminishes cerebral edema on MRI and decreases clinical symptoms of sCRN in irradiated glioma patients. Several non-randomized clinical studies demonstrated a beneficial radiological and clinical effect of bevacizumab in patients with sCRN after irradiation for BM. The optimal first-line treatment for sCRN is currently unknown. Effective and safe first-line treatment of sCRN will optimize the patient's well-being and health-related QoL. Furthermore, minimizing corticosteroid use will benefit the clinical treatment options and outcomes of concomitant or future anti-cancer treatment. This phase III multicenter, open-label, randomized clinical trial compares the clinical efficacy of first-line bevacizumab versus standard-of-care dexamethasone for sCRN in patients with high-grade glioma (HGG) or BM.
This description comes directly from the study's public registry record.
Danique Laan, MSc · +31 20 512 9111 · brains@nki.nl
Dieta Brandsma, MD, PhD · +31 20 512 9111 · brains@nki.nl
Always discuss trial participation with your own doctor first.
| Netherlands Cancer Institute - Antoni van Leeuwenhoek | Amsterdam, Netherlands | Recruiting |
| Amsterdam University Medical Centers, location VUmc and AMC | Amsterdam, Netherlands | Recruiting |
| Leiden University Medical Center | Leiden, Netherlands | Recruiting |
| Maastricht University Medical Center+ | Maastricht, Netherlands | Not Yet Recruiting |
| Haaglanden Medical Center | The Hague, Netherlands | Recruiting |
| University Medical Center Utrecht | Utrecht, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06888817